A5073003007- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Radiomics and Machine Learning in Medical Imaging
- MRI in cancer diagnosis
- Urologic and reproductive health conditions
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Screening and Detection
- Molecular Biology Techniques and Applications
- AI in cancer detection
- Inflammatory Bowel Disease
- Genital Health and Disease
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Genomics and Diagnostics
- Infant Nutrition and Health
- Ovarian cancer diagnosis and treatment
- Statistical Methods in Clinical Trials
- Gastroesophageal reflux and treatments
Royal Free London NHS Foundation Trust
2020-2022
University College London
2013-2020
University College Hospital
2015-2020
University College London Hospitals NHS Foundation Trust
2013-2018
Faculty (United Kingdom)
2017-2018
Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary improve diagnostic accuracy.
Transrectal ultrasound-guided prostate biopsies are prone to detection errors. Multi-parametric MRI (MP-MRI) may improve the diagnostic pathway.
Men with suspected prostate cancer usually undergo transrectal ultrasound (TRUS)-guided biopsy. TRUS-guided biopsy can cause side effects and has relatively poor diagnostic accuracy. Multiparametric magnetic resonance imaging (mpMRI) used as a triage test might allow men to avoid unnecessary improve To (1) assess the ability of mpMRI identify who safely biopsy, (2) mpMRI-based pathway rate detection clinically significant (CS) compared (3) estimate cost-effectiveness pathway. A validating...
All risk stratification strategies in cancer overlook a spectrum of disease. The Prostate MR Imaging Study (PROMIS) provides unique opportunity to explore cancers that are overlooked by multiparametric magnetic resonance imaging (mpMRI).To summarise attributes systematically mpMRI.PROMIS tested performance mpMRI and transrectal ultrasonography (TRUS)-guided biopsy, using 5 mm template mapping (TPM) biopsy as the reference standard.Outcomes were overall maximum Gleason scores, core length...
5000 Background: Multi-parametric magnetic resonance imaging (MP-MRI) as a triage test might allow men to avoid unnecessary transrectal ultrasound-guided (TRUS) prostate biopsy since many with an elevated PSA do not have clinically significant cancer. Methods: PROMIS (ClinicalTrials.gov/NCT01292291) is prospective, paired-cohort confirmatory study representing level Ib evidence. tested MP-MRI and TRUS-biopsy respect accurate reference test, 5mm sampling of the template mapping (TPM-biopsy)....
False positive multiparametric magnetic resonance imaging (mpMRI) phenotypes prompt unnecessary biopsies. The Prostate MRI Imaging Study (PROMIS) provides a unique opportunity to explore such in biopsy-naïve men with raised prostate-specific antigen (PSA) and suspected cancer. To compare mpMRI lesions with/without significant cancer on transperineal mapping biopsy (TPM). PROMIS participants (n = 235) underwent followed by combined procedure at University College London Hospital, including...
Abstract Objectives: The rationale for directing targeted biopsy towards the centre of lesions has been questioned in light prostate cancer grade heterogeneity. In this study, we assess assumption that maximum Gleason (Gleason hotspot) lies within dimension (volume a lesion. Methods: 3-D histopathological models were reconstructed using outputs 5-mm transperineal mapping (TPM) biopsies used as reference test pilot phase Prostate Mri Imaging Study (PROMIS), paired validating cohort study...
We evaluated the performance of transrectal ultrasound guided systematic and transperineal template mapping biopsies with a 5 mm sampling frame stratified by multiparametric magnetic resonance imaging Likert score in PROMIS (Prostate MR Imaging Study).
Background The effects of regional histopathologic changes on prostate MRI scans have not been accurately quantified in men with an elevated prostate-specific antigen (PSA) level and no previous biopsy. Purpose To assess how Gleason grade, maximum cancer core length (MCCL), inflammation, prostatic intraepithelial neoplasia (PIN), or atypical small acinar proliferation within a Barzell zone affects the odds visibility. Materials Methods In this secondary analysis Prostate Imaging Study...
Abstract Gleason score 7 prostate cancer with a higher proportion of pattern 4 (G4) has been linked to genomic heterogeneity and poorer patient outcome. The current assessment G4 uses estimation by pathologist, more likely trigger additional imaging treatment over active surveillance. This method shown have inter-observer variability. Fifteen patients Prostate Grade Group (GG) 2 (Gleason 3 + 4) fifteen GG3 3) disease were selected from the PROMIS study 192 haematoxylin eosin-stained slides...
You have accessJournal of UrologyProstate Cancer: Detection & Screening IV1 Apr 2017MP38-07 SHOULD WE AIM FOR THE CENTRE OF AN MRI PROSTATE LESION? CORRELATION BETWEEN MPMRI AND 3-DIMENSIONAL 5MM TRANSPERINEAL MAPPING BIOPSIES FROM PROMIS TRIAL Clement Orczyk, Yi Peng Hu, Eli Gibson, Ahmed El-Shater Bosaily, Alex Kirkham, Shonit Punwani, Louise Brown, Esther Bonmati, Yolana Coraco-Moraes, Katie Ward, Rick Kaplan, Dean Barratt, Mark Emberton, and Hashim U OrczykClement Orczyk , HuYi Hu...
Over the last 10 yr, multiparametric magnetic resonance imaging (mp-MRI) has been suggested as a diagnostic test capable of detecting and ruling out clinically significant gland-confined prostate cancer before biopsy. The poor methodologic quality many initial studies [1Kirkham A.P. Emberton M. Allen C. How good is MRI at characterising within prostate?.Eur Urol. 2006; 50: 1163-1174Abstract Full Text PDF PubMed Scopus (309) Google Scholar, 2Ahmed H.U. Kirkham A. Arya et al.Is it time to...
You have accessJournal of UrologyProstate Cancer: Detection & Screening IV (MP30)1 Apr 2019MP30-08 COMPARISON OF TRUS-BIOPSY TO TRANSPERINEAL TEMPLATE MAPPING BIOPSIES STRATIFIED BY MRI SCORE WITHIN THE PROMIS TRIAL Catherine Lovegrove*, Louise Brown, Saiful Miah, Ahmed El-Shater Bosaily, Richard Kaplan, Alex Freeman, Kirkham, Mathias Winkler, Raj Persad, Hindley, Robert Oldroyd, Tim Dudderidge, Derek Rosario, Nick Burns-Cox, Iqbal Shergill, Simon Bott, Alastair Henderson, Christopher...
You have accessJournal of UrologyProstate Cancer: Detection & Screening VIII (MP81)1 Apr 2020MP81-19 WHICH PROSTATE CANCERS ARE OVERLOOKED BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING? AN ANALYSIS FROM PROMIS Joseph Norris*, Lina Carmona Echeverria, Simon Bott, Louise Brown, Nicholas Burns-Cox, Timothy Dudderidge, Ahmed El-Shater Bosaily, Elena Frangou, Alex Freeman, Maneesh Ghei, Alastair Henderson, Richard Hindley, Kaplan, Kirkham, Robert Oldroyd, Christopher Parker, Raj Persad, Shonit...
You have accessJournal of UrologyProstate Cancer: Detection & Screening IV1 Apr 2014MP67-19 MORPHOLOGICAL ASSESSMENT OF ANTERIOR LESIONS ON PROSTATE MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING. Ahmed El-Shater Bosaily, Alex Freeman, Mark Emberton, Hashim Ahmed, and Kirkham BosailyAhmed Bosaily More articles by this author , FreemanAlex Freeman EmbertonMark Emberton AhmedHashim KirkhamAlex View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2086AboutPDF ToolsAdd to...
You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy I1 Apr 2017MP70-02 CORRELATION OF MPMRI CONTOURS WITH 3-DIMENSIONAL 5MM TRANSPERINEAL PROSTATE MAPPING BIOPSY WITHIN THE PROMIS TRIAL PILOT: WHAT MARGINS ARE REQUIRED? Clement Orczyk, Yi Peng Hu, Ahmed El-Shater Bosaily, Eli Gibson, Alex Kirkham, Shonit Punwani, Esther Bonmati, Louise Brown, Yolana Coraco-Moraes, Katie Ward, Rick Kaplan, Dean Barratt, Mark Emberton, and Hashim U OrczykClement Orczyk More articles...